BMY Reports Positive Results From Phase 3 Breyanzi Trial In Second-line Relapsed Or Refractory LBCL
NEW YORK CITY (dpa-AFX) - Bristol Myers Squibb (BMY) announced Thursday positive topline results from Phase 3 TRANSFORM trial evaluating Breyanzi (lisocabtagene maraleucel) versus chemotherapy followed by stem cell transplant in second-line relapsed or refractory large B-cell lymphoma or LBCL.
The trial met primary and key secondary endpoints, demonstrating a highly statistically significant improvement in event-free survival, complete response rate and progression-free survival compared to standard of care. Overall survival data were immature at the time of this interim analysis, the company noted.
TRANSFORM global, randomized, multicenter Phase 3 study evaluates Breyanzi (lisocabtagene maraleucel) as a second-line treatment in adults with relapsed or refractory LBCL compared to salvage therapy followed by high-dose chemotherapy and hematopoietic stem cell transplant, which is currently considered a gold standard treatment for these patients.